Supernus Pharmaceuticals | SUPN - Equity Capital And Reserves


Supernus Pharmaceuticals reported $1.06B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.13B 1.3B Dec/2025
ANI Pharmaceuticals USD 505.82M 69.06M Sep/2025
Aurora Cannabis CAD 567.1M 21.58M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 736.01M 247.04M Sep/2025
Cara Therapeutics USD 32.93M 41M Jun/2025
Corcept Therapeutics USD 647.8M 15.9M Dec/2025
Eisai JPY 889.64B 35.21B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Novo Nordisk DKK 194.05B 24.15B Dec/2025
Pacira USD 727.21M 30.55M Sep/2025
Perrigo USD 4.45B 25.8M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Xeris Pharmaceuticals USD -861K 18.44M Sep/2025